Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 49

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

The Great Reconnector: Finding Our Way Back Together With Psychedelics

Breathwork, Holding Space, and the Healing Power of Connection: Documenting the...

Exclusive: David Hough on Lykos’ Path to Resubmission

Psychedelics and Addiction Recovery: Microdosing and Redefining the Path to Sobriety

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to...

Is Psychedelic-Assisted Therapy at a Crossroads? Exploring What’s Next for Lykos...

Empathy and Agency: Why Psychedelic Practitioners Need to be Trauma-Informed

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study?...

The Illinois CURE Act: Shaping the Future of Psychedelic Policy

Regenerative Economics and Psychedelics: Creating More Connected Leadership

Load more

EDITOR PICKS

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant...

The Psychedelic Practitioner Issue 5: Groups in Practice

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©